[Congressional Record Volume 167, Number 42 (Friday, March 5, 2021)]
[Senate]
[Page S1361]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 1300. Mr. BURR submitted an amendment intended to be proposed to 
amendment SA 891 proposed by Mr. Schumer (for himself, Mr. Wyden, Mrs. 
Murray, Mr. Brown, Mr. Peters, Mr. Cardin, Ms. Cantwell, Ms. Stabenow, 
Mr. Tester, Mr. Menendez, Mr. Schatz, Mr. Carper, Mr. Leahy, and Mr. 
Sanders) to the bill H.R. 1319, to provide for reconciliation pursuant 
to title II of S. Con. Res. 5; which was ordered to lie on the table; 
as follows:
        Strike section 2501 and insert the following:

     SEC. 2501. RESEARCH AND DEVELOPMENT OF MEDICAL 
                   COUNTERMEASURES AND ANCILLARY MEDICAL SUPPLIES.

       (a) In General.--In addition to amounts otherwise 
     available, there is appropriated to the Secretary of Health 
     and Human Services (in this subtitle referred to as the 
     ``Secretary'') for fiscal year 2021, out of any money in the 
     Treasury not otherwise appropriated, $7,660,000,000, to 
     remain available through September 30, 2031, necessary 
     expenses with respect to the research, development, 
     manufacturing, production, and purchase, at the discretion of 
     the Secretary, of vaccines, therapeutics, ancillary supplies 
     necessary for the administration of such vaccines and 
     therapeutics, and medical devices to prevent, prepare for, 
     and respond to SARS-CoV-2, or any viral variant mutating 
     therefrom with pandemic potential and COVID-19, or other 
     public health threats, of which--
       (1) $3,064,000,000 shall be for the Biomedical Advanced 
     Research and Development Authority to support the research, 
     advanced research, development, manufacturing, and 
     procurement of medical countermeasures, which may include 
     supporting, maintaining, and improving domestic manufacturing 
     surge capacity of medical products or platform technologies 
     for use during a public health emergency, pursuant to section 
     319L of the Public Health Service Act (42 U.S.C. 247d-7e);
       (2) $1,149,000,000 shall be for the Strategic National 
     Stockpile pursuant to section 319F-2 of the Public Health 
     Service Act (42 U.S.C. 247d-6b) related to the procurement 
     and maintenance of medical products and ancillary medical 
     supplies necessary to respond to public health threats, which 
     may include through the establishment and maintenance of 
     domestic manufacturing surge capacity or vendor managed 
     supply reserves;
       (3) $1,532,000,000 shall be for the National Institutes of 
     Health to support the research and development of medical 
     countermeasures, including broad-spectrum antivirals for 
     SARS-CoV-2;
       (4) $766,000,000 shall be for the Biomedical Advanced 
     Research and Development Authority to support the research 
     and development of broad-spectrum antiviral drugs for SARS-
     CoV-2; and
       (5) $1,149,000,000 shall be for the Secretary for rapid 
     screening, identification, and development of compounds and 
     platform technologies that may support preparedness for and 
     response to a potential public health threat.
                                 ______